Episode Summary
Executive Summary: Omri discusses his path from Israel, military intelligence, and academia to Stanford entrepreneurship and biotech investing. He argues that founder success comes from bias for action, authenticity, and grit, while biotech’s future lies in longevity, fertility, gene editing, and platform technologies that can meaningfully extend healthy life and reshape healthcare.
Main Topics: From scientist to entrepreneur to investor (Priority: 5/5): Omri traces his path from biology PhD/postdoc to founding Genome Compiler, selling to Twist Bioscience, and later launching TechBio and joining NFX as a biotech partner. Military and Israeli roots as entrepreneurial training (Priority: 4/5): He explains how Israeli military service, especially in intelligence/technical units, builds patience, teamwork, resourcefulness, and bias for action that transfer well to startups. Stanford, podcasts, and exposure to entrepreneurship (Priority: 4/5): Stanford’s startup culture and early entrepreneurship podcasts helped him see company-building as an accessible path, especially after years of lab work and commuting. Longevity thesis and the 'Race to 160' (Priority: 5/5): Omri lays out a longevity framework centered on extending healthy lifespan, arguing that aging is the root problem and that society needs to solve longevity and fertility. Biotech’s technical frontiers: reprogramming, senolytics, delivery (Priority: 5/5): He highlights partial reprogramming, senescent-cell removal, CRISPR and delivery systems, and stem-cell-derived embryo models as key approaches in biotech. Founder evaluation: authenticity, intangibles, fundraising (Priority: 5/5): He emphasizes that exceptional founders care deeply, communicate authentically, and often win by fundraising well, not just by having the best science. Exponential thinking, network effects, and Silicon Valley (Priority: 4/5): He argues that understanding exponential growth, being in the right ecosystem, and learning through proximity are central to innovation and venture success.
Key Arguments: Military service can cultivate patience, grit, team coordination, and bias for action—traits that translate directly into entrepreneurship. Stanford and early entrepreneurship podcasts made startup-building legible and inspired him to found a company in synthetic biology. Biology was becoming programmable because the costs of reading and writing DNA were collapsing, creating a software-like opportunity in genomics. Longevity is the future of healthcare; current medicine is mostly 'sick care' that reacts after damage occurs. The biggest biotech opportunities are platform technologies that can impact many diseases, not single-indication drugs. Aging should be attacked through multiple strategies: cryonics, disease-by-disease bioengineering, and especially replacement/young tissue generation. The core bottleneck in gene editing is delivery—getting the payload to the right cells reliably. Founder quality is often revealed by intangibles: deep care, authenticity, communication, persistence, and the ability to keep fundraising and executing. Venture investing is a power-law game; success depends on backing companies that can become multi-billion-dollar outcomes fast. Silicon Valley’s network effects accelerate learning, norm-setting, and opportunity recognition; proximity matters in becoming better at building and investing.
Data Points: Army service duration: 3 years - Regular service for Israeli boys after high school Postdoc duration at Stanford: 4 years - Worked in the medical school lab before founding a company Founding year of Genome Compiler: 2011 - Built software tools for bioengineers CEO tenure at Genome Compiler: 5.5 years - He says the role was physically and mentally rough Sale of Genome Compiler: 2016 - Company sold to Twist Biosciences TechBio fund size: $10 million - Pre-seed fund focused on tech bio Joined NFX: 2020 - Joined in the middle of COVID after NFX invested in his fund Human genome sequencing cost reduction: From $3 billion to less than $100 - Illustrates the dramatic decline in DNA reading costs World record lifespan mentioned: 122 years - Current biological record cited as evidence of current limits US GLP-1 usage prediction: 80% of Americans - He predicts broad future adoption of GLP drugs Population decline example: Japan: Around 2 million people per year - He cites Japan as losing population annually Population decline example: China: From 1.4 billion to 300 million - He mentions a projected end-of-century decline South Korea fertility rate: 0.65 children per woman - Used to illustrate demographic collapse risk Mice lifespan extension via senescent-cell clearing: 30% longer - Cited as evidence for senolytics
Pivotal Quotes: "you only need one thing to be an entrepreneur. You need to get out of the fucking couch and do something." — Omri: Defines entrepreneurship as action-oriented rather than credential-based "I think the best health care is to be healthy, is to be young." — Omri: Summarizes his longevity thesis and critique of reactive medicine "In the future having a regular baby, the old-fashioned way, will be crazy." — Omri: Describes a future where genetic screening, IVF, and reproductive tech become standard
Implications: The conversation points to a future where biotech becomes increasingly software-like, longevity and fertility become major industries, and founders win by combining technical depth with relentless action and authentic conviction.
About We the Builders
Conversations with practitioners at the edge of their craft across business, media, startups, frontier technologies, investing.